Global Tardive Dyskinesia Treatment Market: By Drug Class (Beta blockers, Vitamin E systemic, VMAT2 inhibitors, Dopaminergic agents, Benzodiazepines), By Disorder (Bradykinesia, Hyperkinesia), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Tardive Dyskinesia Treatment Market size is valued at USD 5.68 billion in 2021 and is expected to reach USD 7.22 billion by 2028, at a CAGR of 4.2% during the forecast period 2022-2028. Tardive dyskinesia  is a neurological condition in which involuntary movements are involved. The phrases tardive and dyskinesia can be defined as delayed and aberrant movement, respectively. Finger movement, facial grimacing, jaw swinging, repetitive chewing, constant blinking of the eyes, tongue pushing, and other symptoms of tardive dyskinesia. Tardive dyskinesia is a side effect of neurotic medications. These drugs are also known as anti psychotics or strong tranquilizers. These medications are mostly used to treat mental illnesses. When you use a drug for months or years, you may develop tardive dyskinesia. Because the drug that can be used to treat tardive dyskinesia has not yet been licences, and the method of treatment has not yet been validated, treating the disease is a challenging undertaking. The patient's neurological system is affected by the tardive dyskinesia treatment. Because the drug that can be used to treat tardive dyskinesia has not yet been licenced, and the method of treatment has not yet been validated, treating the disease is a challenging undertaking. The patient's neurological system is affected by the tardive dyskinesia treatment. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Global Tardive Dyskinesia Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

4.2%

Largest Market

North-America

Fastest Growing Market

Europe
Tardive Dyskinesia Treatment Market Dynamics

In the approaching years, the market for tardive dyskinesia treatment will expand dramatically. The increasing number of people suffering from neurological problems is a major element driving the tardive dyskinesia therapy market. The majority of the population in North America suffers from tardive dyskinesia, and individuals are eagerly anticipating treatment, driving the market's growth. The approval process for new treatment modalities by the respective association is a stumbling block to market growth.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Tardive Dyskinesia Treatment Market Segmentation

By Drug Class
  • Beta blockers
  • Vitamin E systemic
  • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
  • Dopaminergic agents
  • Benzodiazepines
By Disorder
  • Bradykinesia
  •  Hyperkinesia
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive Summary
  2. Global Tardive Dyskinesia Treatment Market Introduction
    • Global Tardive Dyskinesia Treatment Market – Taxonomy
    • Global Tardive Dyskinesia Treatment Market –Definitions
      • Drug Class
      • Route of Administration
      • Distribution Channel
  1. Global Tardive Dyskinesia Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Tardive Dyskinesia Treatment Market Dynamic Factors - Impact Analysis
    • Global Tardive Dyskinesia Treatment Market – Competition Landscape
    • Epidemiology
  2. Global Tardive Dyskinesia Treatment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Tardive Dyskinesia Treatment Market, By Drug Class, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Beta blockers
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Vitamin E systemic
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Dopaminergic agents
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Benzodiazepines
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Tardive Dyskinesia Treatment Market Forecast, By Route of Administration,2013 - 2017 and Forecast, 2018 – 2024
    • Oral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Tardive Dyskinesia Treatment Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Tardive Dyskinesia Treatment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Tardive Dyskinesia Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Region, 2018 – 2024
  2. North America Tardive Dyskinesia Treatment MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Beta blockers
      • Vitamin E systemic
      • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
      • Dopaminergic agents
      • Benzodiazepines
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Tardive Dyskinesia Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2018 – 2024
    • North America Tardive Dyskinesia Treatment Market Dynamics – Trends
  3. Europe Tardive Dyskinesia Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Beta blockers
      • Vitamin E systemic
      • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
      • Dopaminergic agents
      • Benzodiazepines
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Tardive Dyskinesia Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2018 – 2024
    • Europe Tardive Dyskinesia Treatment Market Dynamics – Trends
  4. Asia-Pacific Tardive Dyskinesia Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Beta blockers
      • Vitamin E systemic
      • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
      • Dopaminergic agents
      • Benzodiazepines
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Tardive Dyskinesia Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2018 – 2024
    • Asia-PacificTardive Dyskinesia Treatment Market Dynamics – Trends
  5. Latin America Tardive Dyskinesia Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Beta blockers
      • Vitamin E systemic
      • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
      • Dopaminergic agents
      • Benzodiazepines
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Tardive Dyskinesia Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2018 – 2024
    • Latin America Tardive Dyskinesia Treatment Market Dynamics – Trends
  6. Middle East and Africa Tardive Dyskinesia Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Beta blockers
      • Vitamin E systemic
      • VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
      • Dopaminergic agents
      • Benzodiazepines
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Tardive Dyskinesia Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2018 – 2024
    • MEA Tardive Dyskinesia Treatment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Biogen (U.S)
      • Teva Pharmaceutical Industries Ltd. (Israel)
      • GlaxoSmithKline Plc.(U.K)
      • Johnson & Johnson Services, Inc.(U.S)
      • Pfizer Inc.(U.S)
      • Neurocrine Biosciences, Inc.(U.S)
      • Novartis AG(Switzerland)
      • AstraZeneca (U.K)
      • Bayer AG (Germany)
      • Sanofi (France)
  1. Research Methodology
  2. Key Assumptions and Acronyms
Disclaimer The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

  • Biogen (U.S)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline Plc.(U.K)
  • Johnson & Johnson Services, Inc.(U.S)
  • Pfizer Inc.(U.S)
  • Neurocrine Biosciences, Inc.(U.S)
  • Novartis AG (Switzerland)
  • AstraZeneca (U.K)
  • Bayer AG (Germany)
  • Sanofi (France)